Treatment of phantom limb pain with botulinum toxin type a

Pain Medicine

Volumn 10, Issue 2, 2009, Pages 300-303

  Kollewe, Katja ^a   Jin, Lingjing ^a   Krampfl, Klaus ^a   Dengler, Reinhard ^a   Mohammadi, Bahram ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Amputation Stump; Botulinum Toxin; Pain; Phantom Limb

Indexed keywords

BOTULINUM TOXIN A; CARBAMAZEPINE; TRAMADOL; MUSCLE RELAXANT AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGNOSIA; AMPUTATION STUMP; ARTICLE; CASE REPORT; DRUG RESPONSE; DRUG UTILIZATION; ELECTROMYOGRAM; FEMALE; HUMAN; LEG AMPUTATION; MALE; PAIN ASSESSMENT; PAIN THRESHOLD; PHANTOM PAIN; VISUAL ANALOG SCALE; DISABLED PERSON; MIDDLE AGED; PAIN; PHANTOM LIMB;

ADULT; AMPUTEES; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN; PHANTOM LIMB; BOTULINUM TOXINS, TYPE A;

EID: 62349088935     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00554.x     Document Type: Article

References (37)

1. Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001;87:107-16.
2. Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: Results of a survey. Pain 1984;18:83-95.
3. Jensen TS, Krebs B, Nielsen J, Rasmussen P. Immediate and long-term phantom limb pain in amputees: Incidence, clinical characteristics and relationship to pre-amputation limb pain. Pain 1985;21:267-78.
4. Parkes CM. Factors determining the persistence of phantom pain in the amputee. J Psychosom Res 1973;17:97-108.
5. Esquenazi A, Meier RH, 3rd. Rehabilitation in limb deficiency. 4. Limb amputation. Arch Phys Med Rehabil 1996;77:S18-28.
6. Flor H. Phantom-limb pain: Characteristics, causes, and treatment. Lancet Neurol 2002;1:182-9.
7. Sherman RA. Published treatments of phantom limb pain. Am J Phys Med 1980;59:232-44.
8. Sherman RA. Phantom limb pain. Mechanism-based management. Clin Podiatr Med Surg 1994;11:85-106.
9. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000;7:389-94.
10. Kelm S, Gerats G, Chalkiadaki A, Hefter H. [Reduction of pain and muscle spasms by botulinum toxin A]. Nervenarzt 2001;72:302-6.
11. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci 2005;235:1-9.
12. Ney JP, Difazio M, Sichani A, et al. Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: A prospective trial of 60 patients. Clin J Pain 2006;22:363-9.
13. Devor M. Neuropathic pain and injured nerve: Peripheral mechanisms. Br Med Bull 1991;47:619-30.
14. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64.
15. Schwenkreis P, Witscher K, Janssen F, et al. Changes of cortical excitability in patients with upper limb amputation. Neurosci Lett 2000;293:143-6.
16. Karl A, Birbaumer N, Lutzenberger W, Cohen LG, Flor H. Reorganization of motor and somatosensory cortex in upper extremity amputees with phantom limb pain. J Neurosci 2001;21:3609-18.
17. Wu CW, Kaas JH. The effects of long-standing limb loss on anatomical reorganization of the somatosensory afferents in the brainstem and spinal cord. Somatosens Mot Res 2002;19:153-63.
18. Mannion RJ, Woolf CJ. Pain mechanisms and management: A central perspective. Clin J Pain 2000;16:S144-56.
19. Hazelgrove JF, Rogers PD. Phantom limb pain - A complication of lower extremity wound management. Int J Low Extrem Wounds 2002;1:112-24.
20. Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: A central neuropathic disorder maintained by peripheral input. Pain 1996;67:69-77.
21. Jaeger H, Maier C. Calcitonin in phantom limb pain: A double-blind study. Pain 1992;48:21-7.
22. Finsen V, Persen L, Lovlien M, et al. Transcutaneous electrical nerve stimulation after major amputation. J Bone Joint Surg 1988;70:109-12.
23. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.
24. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002;18:S142-6.
25. Royal MA. Botulinum toxins in pain management. Phys Med Rehabil Clin N Am 2003;14:805-20.
26. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001;16:907-13.
27. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-7.
28. Wheeler AH. Myofascial pain disorders: Theory to therapy. Drugs 2004;64:45-62.
29. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache 2000;40:231-6.
30. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000;123:669-76.
31. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000;44:106-9.
32. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-58.
33. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol 2001;281:H2124-32.
34. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(suppl1):S9-15.
35. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-33.
36. Kern U, Martin C, Scheicher S, Muller H. Does botulinum toxin A make prosthesis use easier for amputees? J Rehabil Med 2004;36:238-9.
37. Kern U, Martin C, Scheicher S, Muller H. Effects of botulinum toxin type B on stump pain and involuntary movements of the stump. Am J Phys Med Rehabil 2004;83:396-9.